Reply: Rethinking eGFR Comparisons in SGLT2 Inhibitor Research

J Am Coll Cardiol. 2024 Mar 5;83(9):e89. doi: 10.1016/j.jacc.2023.12.030.

Authors

Safia Chatur¹, Muthiah Vaduganathan¹, Brian Claggett¹, Scott D Solomon²

Affiliations

¹ Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
² Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: ssolomon@bwh.harvard.edu.

PMID: 38418013
DOI: 10.1016/j.jacc.2023.12.030

No abstract available

Publication types

Letter

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Humans
Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Sodium-Glucose Transporter 2 Inhibitors
Hypoglycemic Agents